Avadel Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Greg Divis
Chief executive officer
US$985.2k
Total compensation
| CEO salary percentage | 60.9% |
| CEO tenure | 5.8yrs |
| CEO ownership | n/a |
| Management average tenure | 4.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
Oct 16
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$73m |
| Jun 30 2024 | n/a | n/a | -US$106m |
| Mar 31 2024 | n/a | n/a | -US$157m |
| Dec 31 2023 | US$985k | US$600k | -US$160m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$142m |
| Dec 31 2022 | US$754k | US$561k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$90m |
| Dec 31 2021 | US$3m | US$545k | -US$77m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$3m | US$520k | US$7m |
| Sep 30 2020 | n/a | n/a | US$16m |
| Jun 30 2020 | n/a | n/a | US$18m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$1m | US$472k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$94m |
| Jun 30 2019 | n/a | n/a | -US$101m |
| Mar 31 2019 | n/a | n/a | -US$96m |
| Dec 31 2018 | US$685k | US$417k | -US$95m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | US$30m |
| Dec 31 2017 | US$1m | US$375k | US$68m |
Compensation vs Market: Greg's total compensation ($USD985.20K) is below average for companies of similar size in the US market ($USD3.19M).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
CEO
Greg Divis (57 yo)
5.8yrs
Tenure
US$985,200
Compensation
Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$985.20k | no data | |
| Senior VP | 4.9yrs | US$663.14k | 0.084% $ 938.6k | |
| Chief Commercial Officer | 3.8yrs | US$770.95k | 0% $ 0 | |
| General Counsel & Company Secretary | 4.2yrs | no data | 0.0091% $ 102.6k | |
| VP of Corporate and Business Development | 9.3yrs | no data | 0.17% $ 1.9m | |
| Vice President of Sales | 8.3yrs | no data | no data | |
| Vice President of People & Culture | 3.5yrs | no data | no data | |
| Consultant | 5.6yrs | US$982.54k | no data | |
| Senior Vice President of Technical Operations | 4.9yrs | no data | no data | |
| Senior Vice President of Medical & Clinical Affairs | no data | no data | no data |
4.9yrs
Average Tenure
56yo
Average Age
Experienced Management: AVDL's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.4yrs | US$985.20k | no data | |
| Member of Scientific Advisory Board | 19.8yrs | no data | no data | |
| Independent Director | 4.9yrs | US$449.84k | 0.070% $ 781.6k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 7.4yrs | US$459.84k | 0.086% $ 968.4k | |
| Member of Scientific Advisory Board | 19.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.9yrs | US$452.34k | 0.17% $ 2.0m | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairman of the Board | 6.3yrs | US$482.34k | 0.13% $ 1.5m | |
| Independent Director | 6.3yrs | US$452.34k | 0.054% $ 611.0k |
6.3yrs
Average Tenure
62yo
Average Age
Experienced Board: AVDL's board of directors are considered experienced (6.3 years average tenure).